Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » EDTs Business Strategy

This excerpt taken from the ELN 20-F filed Feb 26, 2009.
EDT’s Business Strategy
 
Throughout our nearly 40-year history, we have invested in the development of innovative technologies, particularly in Oral Controlled Release (OCR) platform technologies and technologies for poorly water-soluble compounds. We are focused on profitably growing as a specialty drug delivery business, underpinned by our product development capabilities and drug delivery technologies.


25

Table of Contents

In the near to medium term, we will drive growth through our existing approved licensed products and pipeline of 15 products in clinical development. In addition, we seek to generate new pipeline opportunities by entering into further licensing arrangements with pharmaceutical companies as well as identifying and developing proprietary products as we evolve our specialty pharmaceutical business model. As a leading provider of drug delivery technologies, we will continue to invest in the development and application of novel drug delivery technologies.
 
(ELAN DRUG TECHNOLOGIES CHART)
 
Our strategy, based on our comprehensive product development and proprietary technology platforms, involves two complementary elements:
 
  •  Working with pharmaceutical companies to develop products through the application of our technologies to their pipeline and marketed products; and
 
  •  Selectively developing product candidates based on our proprietary technologies (Proprietary Product Candidates or PPCs) where we originate the product concept and ultimately develop the product to a later stage of development prior to out-licensing or making a decision to continue internal development.
 
Our drug delivery technologies are key to our future business. Today, we have more than 1,700 patent and patent applications around our key technology and product areas.
 
This excerpt taken from the ELN 20-F filed Feb 28, 2008.
EDT’s Business Strategy
 
EDT’s business strategy is focused on profitably growing its business as a specialty pharmaceutical business unit of Elan, underpinned by its product development capabilities and drug delivery technologies. In the near to medium term, EDT will continue to drive growth through its existing approved licensed products and pipeline of 17 products in clinical development. In addition, EDT will seek to generate new pipeline opportunities by entering into further licensing arrangements with pharmaceutical companies, and identifying and developing proprietary products as EDT evolves its specialty pharmaceutical business model.
 
EDT’s strategy, based on its comprehensive product development and proprietary technology platforms, involves two complementary elements:
 
  •  Selectively developing product candidates based on its proprietary technologies (Proprietary Product Candidates or PPCs) where EDT originates the product concept and ultimately develops the product to a later stage of development prior to out-licensing or making a decision to continue development itself, with a view to ultimately marketing the product by itself or in co-promotion with a marketing partner; and
 
  •  Working with pharmaceutical companies to develop products through the application of EDT technologies to their pipeline and marketed products.
 
Development of PPCs involves lower risk, reduced costs and faster development timelines compared to traditional new chemical entity drug development. PPCs are based on existing drugs with known safety and efficacy profiles.
 
EDT intends to implement its strategies in the following manner:
 
1. Progress EDT’s existing pipeline to generate future revenues and value;
 
2. Continue to build and develop EDT’s product pipeline;
 
  3.  Capture an increasing share of revenues on products being developed by EDT through the evolution of its specialty pharmaceutical business strategy;
 
  4.  Continue to maintain EDT’s position as a leading provider of drug optimization solutions to pharmaceutical and biotechnology licensees; and
 
5. Enhance and expand its technologies, products and capabilities.


24

Table of Contents

EXCERPTS ON THIS PAGE:

20-F
Feb 26, 2009
20-F
Feb 28, 2008

RELATED TOPICS for ELN:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki